Overview

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Status:
RECRUITING

Trial end date:
2028-02-01

Target enrollment:

Participant gender:

Summary

To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Cetuximab
defactinib